Cue Biopharma (CUE) Revenue & Revenue Breakdown
Cue Biopharma Revenue Highlights
Latest Revenue (Y)
$5.49M
Latest Revenue (Q)
$1.72M
Cue Biopharma Revenue by Period
Cue Biopharma Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $5.49M | 340.88% |
| 2022-12-31 | $1.25M | -91.67% |
| 2021-12-31 | $14.94M | 373.68% |
| 2020-12-31 | $3.15M | -8.78% |
| 2019-12-31 | $3.46M | 202.64% |
| 2018-12-31 | $1.14M | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2015-12-31 | - | - |
Cue Biopharma generated $5.49M in revenue during NA 2023, up 340.88% compared to the previous quarter, and up 480.48% compared to the same period a year ago.
Cue Biopharma Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $1.72M | -5.71% |
| 2023-12-31 | $1.82M | -13.29% |
| 2023-09-30 | $2.10M | 51.95% |
| 2023-06-30 | $1.38M | 639.04% |
| 2023-03-31 | $187.00K | 23.66% |
| 2022-12-31 | $151.23K | 122.39% |
| 2022-09-30 | $68.00K | 161.54% |
| 2022-06-30 | $26.00K | -97.40% |
| 2022-03-31 | $1.00M | -87.89% |
| 2021-12-31 | $8.25M | 244.65% |
| 2021-09-30 | $2.40M | -12.56% |
| 2021-06-30 | $2.74M | 76.37% |
| 2021-03-31 | $1.55M | 226.72% |
| 2020-12-31 | $475.32K | -32.48% |
| 2020-09-30 | $704.00K | -34.51% |
| 2020-06-30 | $1.07M | 19.44% |
| 2020-03-31 | $900.00K | -14.20% |
| 2019-12-31 | $1.05M | 6.61% |
| 2019-09-30 | $984.00K | -6.73% |
| 2019-06-30 | $1.05M | 185.14% |
| 2019-03-31 | $370.00K | 11.92% |
| 2018-12-31 | $330.60K | -26.37% |
| 2018-09-30 | $449.00K | 161.05% |
| 2018-06-30 | $172.00K | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2016-09-30 | - | - |
Cue Biopharma generated $1.72M in revenue during Q1 2024, up -5.71% compared to the previous quarter, and up 1135.38% compared to the same period a year ago.
Cue Biopharma Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| FENC | Fennec Pharmaceuticals | $21.64M | $25.26M |
| TCRX | TScan Therapeutics | $21.05M | - |
| HOOK | HOOKIPA Pharma | $20.13M | - |
| COYA | Coya Therapeutics | $6.00M | $3.43M |
| CUE | Cue Biopharma | $5.49M | $1.72M |
| TFFP | TFF Pharmaceuticals | $733.87K | $650.22K |
| ANIX | Anixa Biosciences | $210.00K | - |
| XFOR | X4 Pharmaceuticals | - | $563.00K |
| DAWN | Day One Biopharmaceuticals | - | $20.07M |
| INAB | IN8bio | - | - |
| CGTX | Cognition Therapeutics | - | - |
| ELYM | Eliem Therapeutics | - | - |
| TERN | Terns Pharmaceuticals | - | - |
| DRMA | Dermata Therapeutics | - | - |
| PYPD | PolyPid | - | - |
| LTRN | Lantern Pharma | - | - |
| INMB | INmune Bio | $-155.00K | - |
CUE Revenue FAQ
What is Cue Biopharma’s yearly revenue?
Cue Biopharma's yearly revenue for 2023 was $5.49M, representing an increase of 340.88% compared to 2022. The company's yearly revenue for 2022 was $1.25M, representing a decrease of -91.67% compared to 2021. CUE's yearly revenue for 2021 was $14.94M, representing an increase of 373.68% compared to 2020.
What is Cue Biopharma’s quarterly revenue?
Cue Biopharma's quarterly revenue for Q1 2024 was $1.72M, a -5.71% decrease from the previous quarter (Q4 2023), and a 818.18% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $1.82M, a -13.29% decrease from the previous quarter (Q3 2023), and a 1104.15% increase year-over-year (Q4 2022). CUE's quarterly revenue for Q3 2023 was $2.1M, a 51.95% increase from the previous quarter (Q2 2023), and a 2988.24% increase year-over-year (Q3 2022).
What is Cue Biopharma’s revenue growth rate?
Cue Biopharma's revenue growth rate for the last 3 years (2021-2023) was -63.26%, and for the last 5 years (2019-2023) was 58.76%.